Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RARB | P10826 | 4/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9402625 | 0.94 | PLA2G2A (0.77) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL2771698 | 0.94 | MAPT (0.58) | PLA2G2ATP53TSHRMAPTRAB9A | |
| SCHEMBL3858281 | 0.92 | PLA2G2A (0.59) | PLA2G2ATP53TSHRPLA2G4BMAPT | |
| SCHEMBL3077835 | 0.90 | PLA2G2A (0.80) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL17413301 | 0.89 | PLA2G2A (0.63) | PLA2G2ATP53TSHRPLA2G4BMAPT | |
| SCHEMBL28627609 | 0.89 | PLA2G2A (0.77) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL89430 | 0.88 | PLA2G2A (0.54) | PLA2G2APLA2G4BMAPTNR1H4RAB9A | |
| SCHEMBL7089932 | 0.87 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BMAPT | |
| SCHEMBL9402623 | 0.87 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BMAPT | |
| SCHEMBL1822124 | 0.87 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109485573-B | Aromatic dicarboxylic acid ionic liquid and preparation method and application thereof | 宝鸡文理学院 | 2021-04-30 | — | — | CN | disclosed |
| CN-102958912-B | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2015-01-14 | — | — | CN | disclosed |
| CN-102958912-A | Benzohydrol derivatives, a preparation process and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2013-03-06 | — | — | CN | disclosed |
| CN-102372653-A | Diphenyl methanol derivative, preparation method thereof and application of diphenyl methanol derivative in medicine | JIANGSU HENGRUI MEDICINE CO | 2012-03-14 | — | — | CN | disclosed |
| WO-2012019428-A1 | BENZOHYDROL DERIVATIVES, A PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | PLA2G2A 993/4885TP53 4727/4885TSHR 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.